Abstract
Background/Aim: While blood neutrophil-tolymphocyte ratio (NLR) has been associated with poor prognosis in NSCLC, however few studies have focused on pleural fluid white blood cell differential count. We conducted a retrospective multicenter cohort study to evaluate the predictive value of pleural NLR in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE). Patients and Methods: From the multicenter lung cancer cohort, 134 epidermal growth factor receptor (EGFR) wild-type patients with NSCLC were selected for evaluation. Receiver operating characteristic (ROC) curve analysis was performed for pretreatment pleural NLR to determine the cut-off value for predicting disease progression within 100 days after the diagnosis. Results: The low-pleural NLR group showed significantly longer overall survival (OS) and progression free survival (PFS) compared to the high-pleural NLR group. After stratification using quartile cut-off values of pleural NLR, the correlation between risk of disease progression and pleural NLR was shown to be dose-dependent. The multivariate analysis on PFS showed that high-pleural NLR (p=0.004) was an independent predictor for shorter PFS with HR of 1.036 (1.011-1.061). Conclusion: Increased pleural NLR is predictive of early disease progression in EGFR mutation wild-type NSCLC patients with MPE.
| Original language | English |
|---|---|
| Pages (from-to) | 2179-2185 |
| Number of pages | 7 |
| Journal | In Vivo |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2020 |
Bibliographical note
Publisher Copyright:© 2020 International Institute of Anticancer Research. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Malignant pleural effusion
- Non-small cell lung cancer
- Pleural neutrophil-to-lymphocyte ratio
Fingerprint
Dive into the research topics of 'Pleural neutrophil-to-lymphocyte ratio may be associated with early disease progression in stage IV non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver